Brain Cancer Vaccine Clinical Trial Ongoing at NYU
A clinical trial to evaluate a brain cancer vaccine in newly-diagnosed brain cancer patients has begun at NYU Medical Center. The study will assess the effect of giving the vaccine following standard therapy with surgery and chemotherapy in patients with glioblastoma multiforme (GBM). GBM is a form of brain cancer which is highly life-threatening.
The vaccine, called DCVax-Brain, incorporates proteins found in patients’ tumors and is designed to attack cancer cells containing these proteins. The study underway at NYU Medical Center is an expansion of an earlier phase I trial of the vaccine.
The trial will enroll patients 18 to 65 years old with newly diagnosed GBM. These will receive standard primary treatment with surgery, followed by radiation with concurrent chemotherapy. Enrolled patients will be randomized to receive the standard of care, and others will receive the standard of care plus the vaccine.
(Source)